ABI-110 / Avirmax Biopharma - LARVOL DELTA

Avirmax Biopharma Announces Completion of the First Cohort of Patient Enrollment in Clinical Trial of ABI-110, a Gene Therapy for Wet AMD Including PCV (PRNewswire) - "Avirmax Biopharma, Inc...today announced completion of the first cohort of the Phase I/IIa clinical trial of ABI-110, the company's gene therapy drug for the treatment of Wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV)."

Trial status • Age-related Macular Degeneration • Ophthalmology

Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV (PRNewswire) - "Avirmax Biopharma...announced that the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company's first gene therapy drug for the treatment of Wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV)....The Phase 1 clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ABI-110 in patients with Wet AMD and PCV."

Trial status • Wet Age-related Macular Degeneration

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Avirmax Biopharma Inc | Enrolling by invitation ➔ Recruiting

Enrollment status • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) (clinicaltrials.gov) - P1/2 | N=18 | Enrolling by invitation | Sponsor: Avirmax Biopharma Inc | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) (clinicaltrials.gov) - P1/2 | N=18 | Not yet recruiting | Sponsor: Avirmax Biopharma Inc

New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV (PRNewswire) - "Avirmax Biopharma...is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV)....The Phase I/IIa trial will be conducted at multiple clinical sites across the United States and will enroll patients with a diagnosis of wet AMD including PCV. The trial's primary objectives are to assess the safety and tolerability of the AAV vector-mediated gene therapy, while secondary objectives include evaluating its impact on visual acuity."

IND • New P1/2 trial • Wet Age-related Macular Degeneration